IBEX Technologies Inc. (TSX VENTURE:IBT) today reported its financial results
for the nine months ended April 30, 2011. 


FINANCIAL RESULTS FOR THE THIRD QUARTER OF FISCAL 2011 

Sales for the quarter ended April 30, 2011 totaled $597,074, an increase of 27%
as compared to $469,502 in the same period of the prior year. The increase in
sales can be attributed to a return to a normal ordering pattern by one of our
major customers. 


"We are pleased to see a return to more normal selling patterns, however the
strong Canadian dollar continues to have a negative impact on our business
profitability when compared to year-ago", said Paul Baehr, IBEX President and
CEO.


Excluding financial and R&D expenses, operating expenses for the third quarter
ended April 30, 2011 decreased 22% from $659,431 to $451,558. A significant
portion of this reduction was due to an inventory related accounting gain which
will be reversed in the next quarter. 


The Company recorded net earnings of $131,577 compared to net earnings of
$137,927 for the same period year ago. This decrease in net earnings is
principally due to several factors such as:




--  lower currency gains related to forward contracts 
    
--  increase in R&D expenses 
    
--  increase in amortization expenses related to investments in new
    equipment 



Due primarily to investment in inventory and capital assets, cash, cash
equivalents, and marketable securities decreased 11% during the quarter ended
April 30, 2011 to $1,986,434 from $2,231,287 as of January 31, 2011. The
Company's working capital was $2,750,754 as at the end of the third quarter
ended April 30, 2011 up from $2,598,828 as at the end of the prior quarter
ending January 31, 2011. This increase in working capital traces to an increase
in current assets such as inventory and accounts receivable. 


FINANCIAL RESULTS FOR THE YEAR TO DATE 

Reported sales for the nine months ended April 30, 2011 totaled $1,485,699, a
decrease of 25% as compared to $1,987,196 for the same period in the prior year.
This decrease in sales is principally due to a reduction in orders in both the
enzymes and arthritis product lines. The reduction in the enzymes line was due
to a temporary adjustment of inventories by our key customers, whose ordering
pattern has now returned to normal. The reduction in arthritis assays stemmed
from a decrease in the number of arthritis trials conducted by our key
customers.


Research and development expenses for the nine months ended April 30, 2011
totaled $225,021 compared to $7,980 in the nine months ending April 31, 2010. In
the third quarter of fiscal 2010, the Company hired new scientific specialists
to work on its arthritis assays product line and should introduce new assays
with financial benefits in Fiscal 2012. 


Net loss for the nine months ended April 30, 2011 was $199,641, compared to net
earnings of $634,797, for the same period in previous fiscal year. This net loss
is mainly due to lower currency gains made on hedging against the US dollar,
lower sales, and to the increase in R&D expenses.


Excluding R&D and financial expenses, operating costs for the nine months ended
April 30, 2011 decreased to $1,503,945 from $1,762,712, principally due to a
higher inventory allocation (the transfer of expenses to the balance sheet as a
result of producing in current quarters for sale in future quarters), as well as
reduced compensation costs.


Owing primarily to increased investment in inventory and capital assets, cash,
cash equivalents, and marketable securities decreased 34% over the nine months
ended April 30, 2011 to $1,986,434 from $3,033,556 on July 31, 2010. Working
capital decreased to $2,750,754 on April 30, 2011 from $3,278,875 as at July 31,
2010. 




Financial Summary for the nine months ending                              
--------------------------------------------------------------------------
                                            April 30, 2011  April 30, 2010
                                                                          
Revenues                                        $1,485,699      $1,987,196
(Loss) Earnings Before Interests, Tax,                                    
 Depreciation & Amortization                      ($99,730)       $717,180
Depreciation & Amortization                       $117,655         $93,676
Net (Loss) Earnings                              ($199,641)       $634,797
(Loss) Profit per Share                             ($0.01)          $0.03
Cash, Cash Equivalents & Marketable                                       
 Securities                                     $1,986,434      $2,973,894
Working Capital                                 $2,750,754      $3,482,086
Outstanding shares at report date (Common                                 
 Shares)                                        24,703,244      24,703,244



LOOKING FORWARD 

Fiscal 2011 looks to be a difficult year for IBEX due to softness in the US
business environment and the strong Canadian dollar. 


Despite a difficult outlook for Fiscal 2011, we have made two important
investments in our future. IBEX has recently completed a project to add
additional enzyme-related manufacturing capacity, and has also re-established a
small R&D group with the object of adding to our line of arthritis immunoassays
and also improving our existing assays. We expect to introduce new assays in
calendar 2011, with financial benefits accruing in the second half of Fiscal
2012.


ABOUT IBEX 

The Company manufactures and markets a series of proprietary enzymes
(heparinases and chondroitinases). These enzymes are used in pharmaceutical
research, quality assurance, and in the case of Heparinase I, in diagnostic
devices which measure hemostasis in patients.


IBEX also manufactures and markets a series of arthritis assays which are widely
used in pharmaceutical research. These assays enable the measurement of both the
synthesis and degradation of cartilage components, and are powerful tools in the
study of osteo- and rheumatoid arthritis.


For more information, please visit the Company's web site at www.ibex.ca. 

Safe Harbor Statement 

All of the statements contained in this news release, other than statements of
fact that are independently verifiable at the date hereof, are forward-looking
statements. Such statements, based as they are on the current expectations of
management, inherently involve numerous risks and uncertainties, known and
unknown. Some examples of known risks are: the impact of general economic
conditions, general conditions in the pharmaceutical industry, changes in the
regulatory environment in the jurisdictions in which IBEX does business, stock
market volatility, fluctuations in costs, and changes to the competitive
environment due to consolidation or otherwise. Consequently, actual future
results may differ materially from the anticipated results expressed in the
forward-looking statements. IBEX disclaims any intention or obligation to update
these statements. 




--------------------------------------------------------------------------
--------------------------------------------------------------------------
CONSOLIDATED BALANCE SHEETS                                               
--------------------------------------------------------------------------
                                                April 30,        July 31, 
UNAUDITED                                            2011            2010 
--------------------------------------------------------------------------
                                                        $               $ 
ASSETS                                                                    
Current assets                                                            
Cash and cash equivalents                       1,286,434       2,333,556 
Marketable securities                                   -         300,000 
Accounts receivable                               410,154         422,761 
Inventories                                       452,229         226,364 
Prepaid expenses                                  101,730          68,236 
--------------------------------------------------------------------------
Sub-total current assets                        2,250,547       3,350,917 
Long term deposit                                  10,500           8,650 
Marketable securities                             700,000         400,000 
Property and equipment                          1,128,007         760,384 
--------------------------------------------------------------------------
Total assets                                    4,089,054       4,519,951 
--------------------------------------------------------------------------
--------------------------------------------------------------------------
                                                                          
LIABILITIES                                                               
Current liabilities                                                       
Accounts payable and accrued liabilities          199,793         472,042 
--------------------------------------------------------------------------
Total liabilities                                 199,793         472,042 
--------------------------------------------------------------------------
                                                                          
SHAREHOLDERS' EQUITY                                                      
Capital stock                                  52,660,078      52,660,078 
Contributed surplus                               563,753         522,760 
Deficit                                       (49,334,570)    (49,134,929)
--------------------------------------------------------------------------
Total shareholders' equity                      3,889,261       4,047,909 
--------------------------------------------------------------------------
Total liabilities and shareholders' equity      4,089,054       4,519,951 
--------------------------------------------------------------------------
--------------------------------------------------------------------------
                                                                          
                                                                          
--------------------------------------------------------------------------
CONSOLIDATED STATEMENTS OF DEFICIT              April 30,       April 30, 
                                                     2011            2010 
--------------------------------------------------------------------------
                                                        $               $ 
                                                                          
Balance - Beginning of period                 (49,134,929)    (49,641,291)
                                                                          
Net (loss) earnings for the period               (199,641)        634,797 
--------------------------------------------------------------------------
                                                                          
Balance - End of period                       (49,334,570)    (49,006,494)
--------------------------------------------------------------------------
--------------------------------------------------------------------------
                                                                          
                                                                          
                                                                          
CONSOLIDATED STATEMENTS OF EARNING AND COMPREHENSIVE INCOME               
                                                                          
UNAUDITED                                                                 
                               Three months ended       Nine months ended 
                                         April 30                April 30 
--------------------------------------------------------------------------
                                 2011        2010        2011        2010 
--------------------------------------------------------------------------
                                    $           $           $           $ 
                                                                          
Revenue                       597,074     469,502   1,485,699   1,987,196 
--------------------------------------------------------------------------
                                                                          
Operating expenses                                                        
  Research and Development                                                
   expenses                   (84,263)     (7,980)   (225,021)     (7,980)
  Selling, general and                                                    
   administrative expenses                                                
  and cost of goods sold     (401,562)   (633,496) (1,385,840) (1,669,035)
  Amortization of property                                                
   and equipment              (49,996)    (25,935)   (117,655)    (93,676)
  Other interest and bank                                                 
   charges                     (2,370)     (3,161)     (7,331)     (9,796)
  Foreign exchange gain        60,207     353,029      32,763     437,989 
  Writteoff of property                                                   
   and equipment                    -     (21,194)          -     (21,194)
  Investment income            12,487       7,162      17,744      11,293 
--------------------------------------------------------------------------
Total operating expenses     (465,497)   (331,575) (1,685,340) (1,352,399)
--------------------------------------------------------------------------
                                                                          
--------------------------------------------------------------------------
Net earnings (loss) and                                                   
 other comprehensive                                                      
 income                       131,577     137,927    (199,641)    634,797 
--------------------------------------------------------------------------
                                                                          
                                                                          
Net earnings (loss) and                                                   
 other comprehensive                                                      
 income per share                                                         
  Basic and diluted            $ 0.01      $ 0.01      ($0.01)     $ 0.03 
--------------------------------------------------------------------------
--------------------------------------------------------------------------
                                                                          
See accompanying notes                                                    
                                                                          
                                                                          
                                                                          
--------------------------------------------------------------------------
CONSOLIDATED CASH FLOW                                                    
 STATEMENTS                    Three months ended       Nine months ended 
                                         April 30                April 30 
                          ------------------------------------------------
UNAUDITED                        2011        2010        2011        2010 
--------------------------------------------------------------------------
                                    $           $           $           $ 
--------------------------------------------------------------------------
                                                                          
Cash flows provided by                                                    
 (used in):                                                               
Operating activities                                                      
Net earnings (loss) for                                                   
 the period                   131,577     137,927    (199,641)    634,797 
Items not affecting cash -                                                
  Amortization of property                                                
   and equipment               49,996      25,935     117,655      93,676 
  Stock-based compensation                                                
   costs                            -       9,375      40,993      70,155 
  Gain on disposal of                                                     
   property and equipment                       -                       - 
                                                                          
--------------------------------------------------------------------------
Cash flow relating to                                                     
 operating activities         181,573     173,237     (40,993)    798,628 
--------------------------------------------------------------------------
                                                                          
Net changes in non-cash                                                   
 working capital items -                                                  
  (Increase) decrease in                                                  
   accounts receivable       (101,014)    (37,327)     12,607     443,184 
  (Increase) decrease in                                                  
   inventories               (162,241)     37,046    (225,865)     (5,405)
  (Increase) in prepaid                                                   
   expenses                   (73,615)    (92,826)    (35,344)    (39,470)
  (Decrease) increase in                                                  
   accounts payable and                                                   
   accrued liabilities        (61,757)    104,662    (272,249)   (285,700)
--------------------------------------------------------------------------
Net changes in non-cash                                                   
 working capital balances                                                 
 relating to operations      (398,627)     11,555    (520,851)    112,609 
--------------------------------------------------------------------------
Cash flow relating to                                                     
 operating activities        (217,054)    184,792    (561,844)    911,237 
--------------------------------------------------------------------------
                                                                          
Investing activities                                                      
Additions to property and                                                 
 equipment                    (27,799)   (115,788)   (485,280)   (197,688)
                                                -                       - 
--------------------------------------------------------------------------
Cash flow relating to                                                     
 financing activities         (27,799)   (115,788)   (485,280)   (197,688)
--------------------------------------------------------------------------
                                                                          
(Decrease) Increase in                                                    
 cash and cash equivalents                                                
 during the quater           (244,853)     69,004  (1,047,124)    713,549 
--------------------------------------------------------------------------
Cash and cash equivalents                                                 
 - Beginning of period      2,231,287   2,904,890   3,033,558   2,260,345 
--------------------------------------------------------------------------
Cash and cash equivalents                                                 
 - End of period            1,986,434   2,973,894   1,986,434   2,973,894 
--------------------------------------------------------------------------
--------------------------------------------------------------------------

Ibex Technologies (TSXV:IBT)
과거 데이터 주식 차트
부터 11월(11) 2024 으로 12월(12) 2024 Ibex Technologies 차트를 더 보려면 여기를 클릭.
Ibex Technologies (TSXV:IBT)
과거 데이터 주식 차트
부터 12월(12) 2023 으로 12월(12) 2024 Ibex Technologies 차트를 더 보려면 여기를 클릭.